Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 2a Study of PBTZ169

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03334734
Recruitment Status : Terminated (Very slow enrollment)
First Posted : November 7, 2017
Last Update Posted : March 16, 2018
Sponsor:
Collaborator:
OCT LLC
Information provided by (Responsible Party):
Nearmedic Plus LLC

Brief Summary:
Multicenter, open, randomized study with active control (isoniazid) to evaluate the early antibacterial activity, safety and pharmacokinetics of the drug PBTZ169 (capsules 80 mg) when used in patients with first-diagnosed tuberculosis of the respiratory system with bacterial excretion and saved bacterial susceptibility to isoniazid and rifampicin

Condition or disease Intervention/treatment Phase
Tuberculosis Drug: PBTZ169 Drug: Isoniazid Phase 2

Detailed Description:

This phase 2a study is aimed to evaluate the early bactericidal activity of a new anti-tuberculosis drug PBTZ169 (capsules 80 mg), and its results will allow preliminary evaluate antimycobacterial properties of PBTZ169 and confirm a potentially more effective dose for subsequent studies. This study is an open, randomized comparative efficacy (on the parameter of early bactericidal activity), safety and pharmacokinetics study of PBTZ169 in patients with first-diagnosed lung tuberculosis and preserved sensitivity to base antimycobacterial drugs: rifampicin and isoniazid.

Within the framework of the study, it is planned to use the studied drugs (PBTZ169 and isoniazid) as monotherapy within 14 days. Isoniazid is used as a "positive control", that is, in order to determine whether the method of assessing efficacy on the parameter of early bactericidal activity is working.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicenter, Open, Randomized Study With Active Control to Evaluate the Early Bactericidal Activity, Safety and Pharmacokinetics of the Drug PBTZ169 When Used in Patients With First-diagnosed Tuberculosis of the Respiratory System With Bacterial Excretion and Saved Bacterial Susceptibility to Isoniazid and Rifampicin
Actual Study Start Date : December 16, 2016
Actual Primary Completion Date : September 10, 2017
Actual Study Completion Date : February 22, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tuberculosis
Drug Information available for: Isoniazid

Arm Intervention/treatment
Experimental: PBTZ169, 160 mg
2 capsules 80 mg of PBTZ169 once a day for 14 days
Drug: PBTZ169
Once a day for 14 days

Experimental: PBTZ169, 320 mg
4 capsules 80 mg of PBTZ169 once a day for 14 days
Drug: PBTZ169
Once a day for 14 days

Experimental: PBTZ169, 640 mg
8 capsules 80 mg of PBTZ169 once a day for 14 days
Drug: PBTZ169
Once a day for 14 days

Active Comparator: Isoniazid, 600 mg
2 tablets 300 mg of Isoniazid once a day for 14 days
Drug: Isoniazid
Once a day for 14 days




Primary Outcome Measures :
  1. Early bactericidal activity (0-14) [ Time Frame: 14 days after the onset of monotherapy ]

Secondary Outcome Measures :
  1. Early bactericidal activity (0-2) [ Time Frame: 2 days after the onset of monotherapy ]
  2. Early bactericidal activity (0-7) [ Time Frame: 7 days after the onset of monotherapy ]

Other Outcome Measures:
  1. Peak plasma concentration (Сmax) of PBTZ169 [ Time Frame: Up to 72 hours after the last drug administration ]
  2. Minimal plasma concentration (Сmin) of PBTZ169 [ Time Frame: Up to 72 hours after the last drug administration ]
  3. Residual concentration (Ctrough) of PBTZ169 [ Time Frame: Up to 72 hours after the last drug administration ]
  4. Time to reach maximum concentration (Tmax) of PBTZ169 [ Time Frame: Up to 72 hours after the last drug administration ]
  5. Area under the plasma concentration versus time curve in frames [0-24 hours] - AUC(0-24) of PBTZ169 [ Time Frame: Up to 24 hours after the first and last drug administration ]
  6. Area under the plasma concentration versus time curve in frames [0-last concentration above lower limit of quantification (LLoQ)] - AUC(0-t) of PBTZ169 [ Time Frame: Up to 72 hours after the last drug administration ]
  7. Area under the plasma concentration versus time curve in frames [0-∞] - AUC(0-∞) of PBTZ169 [ Time Frame: Up to 72 hours after the last drug administration ]
  8. Area under the plasma concentration versus time curve (AUC) of PBTZ169 [ Time Frame: Up to 72 hours after the last drug administration ]
    Areas under the curve AUC(0-t) and AUC(0-∞), ratio of AUC(0-t) to AUC(0-∞)

  9. Average concentration (Css,av) of PBTZ169 [ Time Frame: Up to 72 hours after the last drug administration ]
  10. Fluctuations (%) in the dosing interval [ Time Frame: Up to 72 hours after the last drug administration ]
    Ratio of (Cmax-Cmin)*100% to Css,av

  11. Total (plasma) clearance (Clt) of PBTZ169 [ Time Frame: Up to 72 hours after the last drug administration ]
  12. Volume of distribution (Vd) of PBTZ169 [ Time Frame: Up to 72 hours after the last drug administration ]
  13. Plasma half-life time (T1/2) of PBTZ169 [ Time Frame: Up to 72 hours after the last drug administration ]
  14. Elimination constant (ke) of PBTZ169 [ Time Frame: Up to 72 hours after the last drug administration ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent received from a volunteer
  • Men and women aged 18 to 65 years, inclusive
  • The first-diagnosed active pulmonary tuberculosis, confirmed by characteristic radiographic changes (infiltration, dissemination, destruction) during radiography or computed tomography of chest organs, without damage to other organs or with the defeat of one or more of the following organs: larynx, trachea, bronchi, lymph nodes
  • The amount of sputum given by the patient is sufficient for carrying out the analyzes provided for by the protocol, but not less than 4-5 ml at the screening
  • The presence of acid-fast mycobacteria in the sputum according to the results of microscopy of smears (1+ and more using the method of microscopy with luminescent dye staining according to the Order of the Ministry of Health of the Russian Federation of March 21, 2003 No. 109, the last edition) and the detection of the DNA of mycobacteria of tuberculosis by the results of molecular genetic methods of diagnosis
  • Body weight not less than 51 kg
  • Body mass index of 18.5-25 kg/m2
  • Ability, according to investigators opinion, to comply with all requirements of the protocol
  • Agreement to use double contraception method during the study participation and for 3 months after the test drug administration - combination of male condom with not less than one of the following methods:

    • female partner using hormonal contraception;
    • using aerosols, creams, suppositories and other agents containing spermicides;
    • female partner using intrauterine device

Exclusion Criteria:

  • Extrapulmonary localization of tuberculosis
  • Presence of resistance to rifampicin and / or isoniazid in the study of sputum samples using molecular genetic methods
  • Admission of any anti-tuberculosis drugs from the moment of diagnosis of tuberculosis to the moment of inclusion in the study
  • The presence of absolute indications for surgical treatment of tuberculosis at the time of screening
  • Positive tests for serological markers of syphilis or HIV infection during screening; active hepatitis or decompensated hepatic cirrhosis
  • Aggravated allergic history, including presence of at least one episode of drug allergy
  • The values of renal and / or hepatic parameters according to laboratory analyzes (taking into account the range of normal laboratory values):

    • Aspartate aminotransferase (AST) level > 2.0 x upper limit of the norm
    • Alanine aminotransferase (ALT) level > 2.0 x upper limit of norm
    • General bilirubin level > 1.5 x upper limit of norm
    • Creatinine level > 1.5 x upper limit of norm
  • Individual drug components intolerance
  • Presence in the anamnesis of malignant neoplasms, except for basal cell skin cancer
  • The presence of severe chronic somatic diseases in the stage of decompensation, including diseases of the cardiovascular, bronchopulmonary, neuroendocrine system, ear, nose and throat (ENT) organs, the gastrointestinal tract, liver, kidneys, blood, skin, or any other somatic or mental diseases that, according to the researcher, prevent the patient from entering the study
  • Gastrointestinal surgeries (except for appendectomy performed not less than 1 year before screening)
  • Mental illness that may interfere with the patient's compliance with the protocol
  • Diabetes mellitus
  • Acute viral and bacterial infections at the time of enrollment or within 2 weeks before enrollment
  • Alcoholism (except in cases when the patient is able, in the opinion of the researcher, to refrain from taking alcohol during the period of participation in the study), drug addiction, abuse of medicines
  • Positive tests for narcotic and psychotropic agents
  • Regular admission or use (including externally) of any hormonal medicines lasting more than 1 week less than 30 days before screening (with the exception of oral hormonal contraceptives and intrauterine spirals containing hormones)
  • Use of cytostatic drugs less than 30 days before screening
  • Multiple admission of drugs with the described in the instructions for medical use adverse events related to nervous system, hemodynamic and hepatic functions with frequencies "very frequent" (≥10%) and "often" (≥1% and <10%) less than 21 days before screening
  • Pregnancy or lactation period
  • Planned conception or sperm donation during the study after the test drug administration or during 3 months after the last date of drug administration
  • Participation in other clinical studies of drugs within less than 3 months before the screening

Layout table for additonal information
Responsible Party: Nearmedic Plus LLC
ClinicalTrials.gov Identifier: NCT03334734     History of Changes
Other Study ID Numbers: PBTZ169-A15-C2A-1
First Posted: November 7, 2017    Key Record Dates
Last Update Posted: March 16, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Nearmedic Plus LLC:
Tuberculosis
PBTZ169
antimycobacterial

Additional relevant MeSH terms:
Layout table for MeSH terms
Tuberculosis
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Isoniazid
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Fatty Acid Synthesis Inhibitors
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents